Diabetes
« Previous EntriesMetformin Is First Preference for Treating Type II Diabetes
Friday, February 10th, 2012Dr. Amir Qaseem, Director of Clinical Policy at ACP and lead author of these newly published guidelines, states, “Most diabetes medications do lower blood sugar, but metformin is more effective since it has fewer side effects and costs less.”
Diabetic patients at a greater risk of succumbing to non-alcoholic liver diseases
Monday, April 11th, 2011New research suggests that patients with Type II diabetes have 70% more chances of dying from liver diseases than non-diabetic patients. The results of the research corroborate with earlier studies which found a direct link between diabetes and liver diseases and also showed that in absence of proper blood-sugar management, risks of developing non-alcoholic fatty [...]
Olmesartan delays microalbuminuria onset in Type 2 diabetics
Tuesday, March 15th, 2011Source: MedWire News
Olmesartan therapy is able to delay the onset of microalbuminuria in patients with Type 2 diabetes, the ROADMAP trial has found.
The Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial was a double-blind multicenter study designed to test whether treatment with an angiotensin receptor blocker (ARB) would delay or prevent the occurrence of microalbuminuria.
The [...]
Pioglitazone-based therapy aids cardiovascular risk control in Type 2 diabetes
Tuesday, March 8th, 2011Source: MedWire News
Pioglitazone in combination with either metformin or a sulfonylurea is an effective second-line therapy for the control of cardiovascular risk factors in patients with Type 2 diabetes, trial results suggest.
Angel Rodríguez (Lilly, S A, Madrid, Spain) and colleagues undertook two multicenter, open-label, prospective, observational trials to evaluate different combination therapies in non-insulin-treated diabetic [...]
Low HDL cholesterol enhances anti-cancer effect of metformin
Monday, February 7th, 2011Source: MedWire News
Research suggests that the previously reported anti-cancer effect of metformin treatment is most apparent in patients with Type 2 diabetes who also have low levels of high-density lipoprotein (HDL) cholesterol.
Several studies, previously reported by MedWire News, have shown that Type 2 diabetes patients who are treated with metformin appear to have a reduced risk [...]
Glimepiride may slow atherosclerosis progression in Type 2 diabetes
Friday, January 28th, 2011Treatment with glimepiride slows progression of carotid intima-media thickness (IMT) to a greater degree than glibenclamide in patients with Type 2 diabetes, suggest results from a small observational study.
“Recent studies reported that glimepiride increased plasma adiponectin levels and decreased plasma tumor necrosis factor-α levels in Type 2 diabetics,” the say researchers.
In addition, “in animal models, [...]
Further evidence for reduced cancer risk with metformin
Wednesday, January 26th, 2011Source: MedWire News
Exposure to metformin is associated with a reduced risk for cancer in patients with Type 2 diabetes, say researchers.
The antidiabetes drug metformin has previously been associated with lower cancer mortality, as reported by MedWire News.
In this study, Edoardo Mannucci (University of Florence, Italy) and co-workers carried out a nested case-control study in a group [...]
Family history, adiposity, HDL cholesterol level predict Type 2 diabetes risk
Thursday, January 20th, 2011Source: MedWire News
Patients with higher than normal fasting plasma glucose (FPG) levels who have a family history of diabetes, have high adiposity, or who have low high-density lipoprotein (HDL) cholesterol levels are at increased risk for developing Type 2 diabetes, research shows.
James Meigs (Massachusetts General Hospital and Harvard Medical School, Boston, USA) and colleagues assessed [...]
U.S. diabetes doubled from 1996 to 2007
Tuesday, January 11th, 2011About 19 million U.S. adults reported receiving diabetes treatment in 2007, more than double the 9 million who received care in 1996, health officials say.
The report by the Agency for Healthcare Research and Quality, part of the Department of Health and Human Services, found that from 1996 to 2007, people age 65 and older treated [...]
Blood pressure extremes increase CVD event risk in diabetic patients
Wednesday, January 5th, 2011Source: MedWire News
High systolic (S) and low diastolic (D) blood pressure (BP) increase the risk for cardiovascular disease (CVD) events in patients with Type 2 diabetes, report researchers from the Veterans Affairs Diabetes Trial (VADT).
Previous research has demonstrated the health benefits of lowering BP in both diabetic and nondiabetic patients with higher than normal values. [...]
